Two trials were conducted with general ED patients, one trial with ED/diabetes patients and one trial with ED/post-prostatectomy patients.

More about Levitra (vardenafil)

This metabolite shows a phosphodiesterase selectivity profile similar to that of vardenafil and an in vitro inhibitory potency for PDE5 28% of that of vardenafil. Therefore, M1 accounts for approximately 7% of total pharmacologic activity. Elimination: The total body clearance of vardenafil is 56 L/h, and the terminal half-life of vardenafil and its primary metabolite (M1) is approximately 4-5 hours. After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered oral dose) and to a lesser extent in the urine (approximately 2-6% of administered oral dose). Pediatrics: Vardenafil is not indicated for use in pediatric patients.

What is tadalafil (Cialis®)?

Vardenafil trials were not conducted in the pediatric population. Geriatric: In a healthy volunteer study of elderly males (≥65 years) and younger males (18-45 years), mean Cmax and AUC were 34% and 52% higher, respectively, in the elderly males. Hepatic Impairment: In volunteers with mild hepatic impairment (Child-Pugh A), the Cmax and AUC following a 10 mg vardenafil dose were increased by 22% and 17%, respectively, compared to healthy control subjects. In volunteers with moderate hepatic impairment (Child- Pugh B), the Cmax and AUC following a 10 mg vardenafil dose were increased by 130% and 160%, respectively, compared to healthy control subjects. Vardenafil has not been evaluated in patients with severe (Child-Pugh C) hepatic impairment.

Can Cialis and Levitra be used together?

Renal Impairment: In male volunteers with ClCr= 50-80 mL/min, the pharmacokinetics of vardenafil were similar to those observed in a control group with ClCr >80 mL/min. In male volunteers with ClCr = 30-50 mL/min or ClCr <30 mL/min renal impairment groups, the AUC of vardenafil was 20-30% higher compared to that observed in a control group with ClCr >80 mL/min). Vardenafil pharmacokinetics have not been evaluated in patients requiring renal dialysis. Advise patients of the contraindication of vardenafil with regular and/or intermittent use of organic nitrates. Patients should be counseled that concomitant use of vardenafil with nitrates could cause blood pressure to suddenly drop to an unsafe level, resulting in dizziness, syncope, or even heart attack or stroke. The fixed doses were 5 mg, 10 mg, and 20 mg daily.

  • Levitra's approval has expanded options for men seeking ED treatment.
  • It is one of several PDE5 inhibitors designed for erectile enhancement.
  • Men should consider potential side effects and interactions before use.
  • Levitra can be taken on an as-needed basis, not necessarily daily.
  • Proper diagnosis of ED involves a thorough medical examination.
  • Persistent ED can be a sign of underlying health issues needing attention.
  • Levitra’s pharmacokinetics allow for flexibility in planning for intimacy.
  • Always follow prescribed instructions to maximize safety and effectiveness.

Primary endpoints were evaluated at 3 months during the trials. For all four trials, the primary endpoints were Erectile Function (EF) Domain score and two aspects of the Sexual Encounter Profile

Product Dosage Quantity + Bonus Price
Levitra Original20mg4 Pills45.87€ 43.69€
Levitra Soft Tabs20mg270 + 10 Pills521.78€ 496.93€
Levitra Original20mg92 + 4 Pills406.22€ 386.88€
Levitra Generic40mg90 + 6 Pills234.73€ 223.55€
Levitra Original20mg8 Pills65.05€ 61.95€
Levitra Soft Tabs20mg180 + 10 Pills398.14€ 379.18€
Levitra Professional20mg90 + 2 Pills304.49€ 289.99€
Levitra Generic40mg10 Pills41.37€ 39.40€
Levitra Generic40mg60 + 4 Pills162.37€ 154.64€
Levitra Generic10mg120 + 10 Pills178.59€ 170.09€
Levitra Generic20mg180 + 10 Pills293.10€ 279.14€

(SEP), i.e., the ability to achieve vaginal penetration (SEP2) and the ability to maintain an erection long enough for successful intercourse (SEP3).

Are there any serious health risks associated with Levitra?

Inform patients of the potential cardiac risk of sexual activity for patients with preexisting cardiovascular risk factors. Inform patients that in some patients concomitant use of PDE5 inhibitors, including vardenafil, with alpha-blockers can lower blood pressure significantly leading to symptomatic hypotension (for example, fainting). Patients prescribed vardenafil who are taking alpha-blockers generic levitra 24 h buy should be started on the lowest recommended starting dose. Patients should be advised of the possible occurrence of symptoms related to postural hypotension and appropriate countermeasures. Patients should be advised to contact the prescribing physician if other anti-hypertensive drugs or new medications that may interact with vardenafil are prescribed by another healthcare provider.

Mild side effects

Discuss with patients the appropriate use of vardenafil and its anticipated benefits. It should be explained that sexual stimulation is required for an erection to occur after taking vardenafil. It should be taken approximately 60 minutes before sexual activity. Patients should be counseled regarding the dosing of vardenafil especially regarding the maximum daily dose. Patients should be advised to contact their healthcare provider for dose modification if they are not satisfied with the quality of their sexual performance with vardenafil or in the case of an unwanted effect.

Related treatment guides

Inform patients that there have been rare reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for vardenafil and this class of compounds. In the event that an erection persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. Advise patients to stop treatment and seek medical attention in the event of sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors. For the trial involving 762 general population ED patients at the 10 mg dose, the EF score, SEP2, and SEP3 in the

Rate drugs

It is not possible to determine whether these events were related directly to the use of PDE5 inhibitors or to other factors. Inform patients of the increased risk of NAION in individuals who have already experienced NAION in one eye and discuss the increased risk of NAION among the general population in patients with a "crowded" optic disc, although evidence is insufficient to support screening of prospective users of PDE5 inhibitor, including vardenafil, for this uncommon condition. Advise patients to stop treatment and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including vardenafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors.

ED Prescriptions for $1-2 Per Pill

The use of vardenafil offers no protection against sexually transmitted diseases. Counseling of patients about protective measure necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), should be considered. Advise patients that the disintegrating tablet (Staxyn) is not interchangeable with the film-coated tablet (Levitra). General Notes: May be taken with or without food. (Tablet) Place on tongue to disintegrate; take without liquid and immediately upon levitra 100 mg removal from blister.

NewYork Weill Cornell Physician Says Drug May Raise Awareness for Treatment of Disease

Approval Status: Approved for marketing by the U.S. FDA on August 19, 2003. Chemical/Biological Nature: LEVITRA is a small molecule chemical compound, with a molecular weight of 579.1 daltons. Administration: LEVITRA is taken orally 60 minutes before sexual activity. For most patients, the recommended starting dose is 10 mg. LEVITRA group were 21 (baseline 13), 75%, and 64%, respectively, compared to 15 (baseline 14), 52%, and 32%, respectively, in the placebo group.

  • Levitra was one of the first medications introduced for erectile dysfunction.
  • Its mechanism involves relaxation of smooth muscle in penile tissue.
  • Men should avoid taking Levitra with heavy meals to ensure rapid action.
  • The medication’s safety profile is well-documented in scientific literature.
  • Levitra may be prescribed alongside other therapies for ED management.
  • Regular medical check-ups are recommended during treatment.
  • Patients should be aware of potential drug interactions with Levitra.
  • Avoid combining Levitra with recreational drugs, especially stimulants.

For the trial involving 439 patients with ED and diabetes at the 10 mg dose, the EF score, SEP2, and SEP3 in the LEVITRA group were 17, 61%, and 49%, respectively, compared to 13, 36%, and 23%, respectively, in the placebo group.

Dosage Frequency Onset Time Duration
5 mg Once daily 25-30 minutes Up to 4 hours
10 mg 1 hour before sex 25-30 minutes Up to 5 hours
20 mg As needed 25-30 minutes Up to 4-5 hours

For the trial involving 427 patients with ED after radical prostatectomy at the 10 mg dose, the EF score, SEP2, and

  • Levitra has been shown to enhance erectile function in clinical studies.
  • It is not classified as a controlled substance but still requires caution.
  • Side effects usually diminish after the body adjusts to the medication.
  • Patients should inform their doctor of all health issues before starting Levitra.
  • In some cases, Levitra may be used temporarily or as needed.
  • Regular blood pressure monitoring is recommended when using Levitra.
  • Levitra should be stored safely away from children and pets.
  • Discuss all medication options with a healthcare provider to find the best treatment.

SEP3 in the LEVITRA group were 15, 47%, and 37%, respectively, compared to 9, 22%, and 10%, respectively, in the placebo group.

  • Levitra is approved for the treatment of erectile dysfunction in men over 18.
  • It is not recommended for use in women or children.
  • The medication is usually taken orally, in tablet form.
  • Levitra's effectiveness relies on sexual stimulation to initiate an erection.
  • Adverse effects are typically mild but can include dizziness and upset stomach.
  • Consult your healthcare provider if you experience prolonged or painful erections.
  • Levitra should be used cautiously in men with liver or kidney disease.
  • Always disclose your complete medical history to ensure safe use.

Adverse Reactions: Patients in the LEVITRA group experienced headache (15%), flushing (11%), rhinitis (9%), dyspepsia (4%), sinusitis (3%), and flu syndrome (3%), compared to 4%, 1%, 3%, 1%, 1%, and 2%, respectively, in the placebo group.

Conditions treated by Levitra and Cialis

Less cGMP is degraded, tilting the balance to a higher level of cGMP, thus enhancing penile erection. It was demonstrated by in vitro studies that LEVITRA inhibits PDE5 selectively. LEVITRA’s inhibitory effect on PDF5 is many more times than that of other PDE types (1, 2, 3, 4, 6, 7, 8, 9, 10, and 11). LEVITRA’s therapeutic effect is contingent on the presence of a sexual stimulation; no sexual stimulation, no release of nitric oxide from nerve endings, and so no effect by LEVITRA. Efficacy and Benefits: Four double-blind, randomized, fixed-dose, multicenter trials involving 2,431 patients were conducted to evaluate the efficacy of LEVITRA. Sexual activities coincide with increased cardiovascular activities and can increase the risk for cardiovascular events.

Is Levitra or Viagra more effective?

Depending on an individual’s response, the dose may be adjusted higher to 20 mg or lower to 5 mg. The recommended maximum dosing frequency is no more than once daily. Mechanism of Disease: Penile erection is a hemodynamic event. There are many abnormalities that could lead to erectile dysfunction. Normally, the signal transduction events mediated by cyclic guanosine monophosphate (cGMP) lead to the relaxation of the smooth muscle of blood vessels that supply blood to the penis when there is sexual stimulation.

Viagra™ Efficacy

The lack of, or insufficient sustained levels of, cGMP result in erectile dysfunction. Mechanism of Drug Action: During sexual stimulation, nitric oxide is released from nerve cells and subsequently from the endothelial cells in the corpus cavernosum of the penis. Nitric oxide activates guanylate cyclase, which catalyzes the synthesis of cGMP from guanosine triphosphate (GTP). cGMP causes the smooth muscle to relax, allowing increased blood flow into the penis, leading to an erection. Because of its importance, the level of cGMP is tightly regulated. Patients with heart conditions should be discouraged from using LEVITRA or other treatments for erectile dysfunction.

Coverage and cost comparison of Levitra vs. Viagra

The balance is maintained by production and degradation. As mentioned above, production of cGMP buy levitra 60mg is initiated after nitric oxide is released. There are numerous types of PDEs, with each type being preferentially expressed in different tissues. The predominant type expressed in the penis is PDE type 5 (PDE5). LEVITRA binds selectively to PDE5 and inhibits the enzymatic function of PDE5.

Scroll to top

Dr. med. Fabienne Gretener

Werdegang

Januar 2024 bis heute
Oberärztin SenoMed AG
Schwerpunktsweiterbildung gynäkologische Senology

März 2023 – Dezember 2023
Oberärztin, SenoMed AG Bern 20%

Januar 2023 – November 2023
Assistenzärztin Psychiatrie, Klinik Meissenberg Zug

Januar 2021 – November 2022
Assistenzärztin Gynecology und Geburtshilfe, Bürgerspital Solothurn

November 2019 – Oktober 2020
Assistenzärztin Gynecology und Geburtshilfe, Kantonsspital Aarau

Januar 2017 – Juli 2019
Assistenzärztin Gynecology und Geburtshilfe, Kantonsspital Olten

Paul Laszlo Bernhard

Werdegang

Jan 2024 bis heute
Facharzt SenoMed AG – Brustzentrum Bern Biel

Aug 2019 – Dez 2023
Oberarzt Frauenklinik und Brustzentrum Bürgerspital, Solothurn, Schwerpunktweiterbildung operative Gynecology und Geburtshilfe sowie Senology

Mai 2019 Facharzttitel Gynecology & Geburtshilfe

Apr 2016 – Jul 2019
Arzt in Weiterbildung, Inselspital Bern, Universitätsklinik für Frauenheilkunde

Dez 2014 – Apr 2016
Arzt in Weiterbildung, Kantonsspital Baden

Sep 2012 – Sep 2014
Arzt in Weiterbildung, Universitätsklinikum Carl Gustav Carus, Dresden

Feb 2012 – Sep 2012
Arzt in Weiterbildung, Universitätsfrauenklinik Leipzig

Nov 2011 Approbation zum Arzt

2005 – 2011
Studium der Humanmedizin an der Charité, Universitätsmedizin Berlin

Dr. med. Patrizia Sager

Werdegang

Okt 2023 bis heute
Leiterin Weiterbildungsstätte gynäkologische Senology

Feb 2018 – bis heute
Leiterin Brustzentrum Bern Biel
Practiceinhaberin SenoMed AG

Nov 2017 – bis heute
Belegärztin Salem-Spital Bern

Jan 2013 – Okt 2017
Leitung Senology Brustzentrum Frauenklinik Universitätsspital Insel, Bern

Jan 2012 – Dez 2012
Oberärztin Gynecology / Geburtshilfe, Frauenklinik Universitätsspital Insel, Bern

Nov 2010 – Dez 2011
Leitende Ärztin Gynecology und Geburtshilfe, Frauenklinik Rheinfelden (DE)

Nov 2009 – Okt 2010
Oberärztin Gynecology und Geburtshilfe, Kantonsspital Liestal

Jan 2009 – Okt 2009
Oberärztin i.V. Gynecology und Geburtshilfe, Regionalspital Interlaken

Jun 2008 – Dez 2008
Assistenzärztin Gynecology und Geburtshilfe, Regionalspital Interlaken

Aug 2007 – Mai 2008
Assistenzärztin Gynecology und Geburtshilfe, Universitätsspital Zürich

Feb 2007 – Jun 2007
Oberärztin Gynecology und Geburtshilfe, Universitätsspital Groote Schuur, Kapstadt, Südafrika

Jan 2004 – Dez 2006
Assistenzärztin Gynecology und Geburtshilfe, Regionalspital Thun

Jan 2003 – Dez 2003
Assistenzärztin Chirurgie und Orthopädie, Regionalspital Thun

Schulen, Studium & Diplome

2023
Schwerpunkt gynäkologische Senology

2014
Diplom Senology SGGG

2013
Diplom Senology: European Academy of Senology

2010
FMH Gynecology und Geburtshilfe inkl. Schwerpunkt operative Gynecology

2003
Promotion

2002
Staatsexamen in Humanmedizin

1996 – 2002
Humanmedizinstudium Universitätsspital Basel

Mitglied- und Partnerschaften

  • Schweizerische Gesellschaft für Gynecology und Geburtshilfe SGGG
  • Schweizerische Gesellschaft für Senology SGS
  • Mitglieder Arbeitsgemeinschaft Gynäkologische Onkologie AGO, Schweiz
  • European Academy of Senology EAoS
  • SAKK Project-Group breast cancer
  • Schweizerische Gesellschaft für Ultraschall in der Medizin SGUM
  • Verbindung der Schweizer Ärzte und Ärztinnen FMH
  • Society of women in senology SWIS
  • Vorstandsmitglied Ärztenetzwerk Bern